ArticleClinical epigenetics2026
A targeted epigenetic clock for simultaneous assessment of biological aging and cancer-associated methylation drift.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: A targeted epigenetic clock for simultaneous assessment of biological aging and cancer-associated methylation drift.Clinical epigenetics · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
backgroundAs a key tool for assessing aging, DNA methylation clocks are mostly constructed based on European and American populations and rely on the high-cost Infinium MethylationEPIC microarray. These factors limit their widespread application in the Chinese population.
methodsThis study included two independent cohorts: the Fuyang cohort (n = 610, age range 2-89 years) for model development, and the Hefei cohort (n = 188, age range 15-86 years) for external validation. Using a multiplex PCR-based targeted capture sequencing technology, we examined 74 CpG sites located in seven age-associated genes, including ELOVL2, FHL2, C1orf132, KLF14, TRIM59, CCDC102B and PDE4C, to construct a DNA methylation-based age prediction model suitable for the Chinese population.
resultsThe performance of our model was consistent with that reported in the literature for this field. In the Fuyang cohort, the training set achieved R
conclusionThis study developed a cost-effective, targeted methylation clock for the full age spectrum in the Chinese population. Its strong response to both physiological aging and tumor status underscores its potential for large-scale aging assessment and for translational applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.